Literature DB >> 23245584

Unexpected close surgical margin in resected buccal cancer: very close margin and DAPK promoter hypermethylation predict poor clinical outcomes.

Hon-Yi Lin1, Tze-Ta Huang, Moon-Sing Lee, Shih-Kai Hung, Ru-Inn Lin, Chih-En Tseng, Shu-Mei Chang, Wen-Yen Chiou, Feng-Chun Hsu, Wen-Lin Hsu, Dai-Wei Liu, Yu-Chieh Su, Szu-Chi Li, Michael W Y Chan.   

Abstract

OBJECTIVES: In resected buccal cancer patients, an unexpected close surgical margin has been observed to correlate with poor clinical outcomes. However, close surgical margin alone does not independently guide post-operative therapies, revealing a clinical debate. Hence, the present study intended to explore epigenetic-based bio-predictors for further stratifying this debating patient population.
MATERIALS AND METHODS: Between 2000 and 2008, we retrospectively recruited 44 resected buccal cancer patients with a close surgical margin of ≤5 mm. All patients had post-operative radiotherapy. Genomic DNA was extracted from tumor-enrich areas that contained cancer cells of >70%. Methylation-specific PCR was performed to detect promoter methylation of four tumor suppressor genes, including RASSF1A, DAPK, IRF8, and SFRP1. Post-irradiation locoregional control was defined as the primary end point.
RESULTS: There were 40 males and 4 females, with a median age of 53.5 years (range, 32-82 years). Multivariate analysis identified two independent predictors for locoregional recurrence: very close margin of ≤1 mm (HR: 4.96; 95% CI, 1.63-15.09; P=0.018) and promoter hypermethylation of DAPK (HR: 2.83; 95% CI, 1.05-7.63; P=0.042). The highest risk of locoregional recurrence was observed in patients with both of the two factors (HR, 8.05; 95% CI, 2.56-25.82; P=0.002) when compared with patients with none. Shorter disease-free survival, but not overall survival, was also observed.
CONCLUSION: More aggressive managements should be considered in resected buccal cancer patients with both very close margin and DAPK promoter hypermethylation rather than post-operative observation or radiotherapy alone.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23245584     DOI: 10.1016/j.oraloncology.2012.11.005

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  4 in total

1.  Guidelines for the Surgical Management of Oral Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Young-Hoon Joo; Jae-Keun Cho; Bon Seok Koo; Minsu Kwon; Seong Keun Kwon; Soon Young Kwon; Min-Su Kim; Jeong Kyu Kim; Heejin Kim; Innchul Nam; Jong-Lyel Roh; Young Min Park; Il-Seok Park; Jung Je Park; Sung-Chan Shin; Soon-Hyun Ahn; Seongjun Won; Chang Hwan Ryu; Tae Mi Yoon; Giljoon Lee; Doh Young Lee; Myung-Chul Lee; Joon Kyoo Lee; Jin Choon Lee; Jae-Yol Lim; Jae Won Chang; Jeon Yeob Jang; Man Ki Chung; Yuh-Seok Jung; Jae-Gu Cho; Yoon Seok Choi; Jeong-Seok Choi; Guk Haeng Lee; Phil-Sang Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-02-02       Impact factor: 3.372

2.  DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcome-predicting and treatment-implicating study.

Authors:  Hon-Yi Lin; Shih-Kai Hung; Moon-Sing Lee; Wen-Yen Chiou; Tze-Ta Huang; Chih-En Tseng; Liang-Yu Shih; Ru-Inn Lin; Jora M J Lin; Yi-Hui Lai; Chia-Bin Chang; Feng-Chun Hsu; Liang-Cheng Chen; Shiang-Jiun Tsai; Yu-Chieh Su; Szu-Chi Li; Hung-Chih Lai; Wen-Lin Hsu; Dai-Wei Liu; Chien-Kuo Tai; Shu-Fen Wu; Michael W Y Chan
Journal:  Oncotarget       Date:  2015-01-20

3.  Analysis of Site-Specific Methylation of Tumor-Related Genes in Head and Neck Cancer: Potential Utility as Biomarkers for Prognosis.

Authors:  Kiyoshi Misawa; Daiki Mochizuki; Atsushi Imai; Masato Mima; Yuki Misawa; Hiroyuki Mineta
Journal:  Cancers (Basel)       Date:  2018-01-22       Impact factor: 6.639

4.  IRAK2, an IL1R/TLR Immune Mediator, Enhances Radiosensitivity via Modulating Caspase 8/3-Mediated Apoptosis in Oral Squamous Cell Carcinoma.

Authors:  Chih-Chia Yu; Michael W Y Chan; Hon-Yi Lin; Wen-Yen Chiou; Ru-Inn Lin; Chien-An Chen; Moon-Sing Lee; Chen-Lin Chi; Liang-Cheng Chen; Li-Wen Huang; Chia-Hui Chew; Feng-Chun Hsu; Hsuan-Ju Yang; Shih-Kai Hung
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.